METHYLOMIC_EU

We intend to clinically validate a biomarker tool based on DNA methylation determining optimal treatment selection for Crohn's disease patients and also expand to RA and psoriasis. Partners in this project are: Alimentiv, AmsterdamUMC, Asphalion, BIRD Group, EFCCA, Descin, Diagenode, Genome Diagnostics, Ghent University, HORAIZON, Instituto de Medicine Molecular Joao Lobo Antunes, Kings College London, Twist Bioscience, University Medical Centre Ljubljana, University of Oxford, University of Szeged, Vita-Salute San Raffaele University, VU University. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101095449.